Italian-based Stevanato Group, a leading producer of glass primary packaging and provider of integrated capabilities for combination products and Duoject Medical Systems, a Canadian-based developer of innovative drug delivery systems, have entered int an exclusive partnership to collaborate on providing bio-pharmaceutical clients a more complete and comprehensive ‘one stop shop’ solution to an emergency-use auto-injector.
The Maverick auto-injector was designed by Duoject Medical Systems, focusing on improving the functionality of auto-injectors to enhance disease management and treatment. Maverick is an innovative cartridge-based auto-injector with a two-step triggered automatic injection and needle retraction. Its user-friendly design allows an easier activation while the needle is not exposed and automatically retracted after injection. Mechanical robustness is a key feature of Maverick, utilizing a highly resistant glass cartridge, which makes it suitable for emergency use where effective and fast intramuscular injection is required.
Stevanato Group is working closely with Duoject Medical Systems to promote this device to bio-pharmaceutical clients that are looking for a suitable auto-injector which is cartridge-based rather than PFS-based and taking into consideration the automatic needle insertion and retraction design of the device. Design for manufacturing and design for assembly will be supported by Stevanato Group. The final device design for clinical trial and commercial launch will be produced at Stevanato Group’s ISO13485 and FDA-audited manufacturing facility in Germany, a key location within the Group for the manufacturing of self-injection devices like auto-injectors. Sub-assembly and final assembly equipment will be primarily produced by Stevanato Group operations in Denmark. Novocol Pharma, parent company of Duoject Medical Systems, will provide extensive support to related bio-pharmaceutical companies in terms of formulation, fill & finish and final assembly of the auto-injector.